Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Share-based Compensation (2016 - 2025)

Neurocrine Biosciences' Share-based Compensation history spans 16 years, with the latest figure at $58.6 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 11.75% year-over-year to $58.6 million; the TTM value through Dec 2025 reached $217.9 million, up 11.46%, while the annual FY2025 figure was $217.9 million, 11.46% up from the prior year.
  • Share-based Compensation reached $58.6 million in Q4 2025 per NBIX's latest filing, up from $53.7 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $68.5 million in Q2 2023 to a low of $28.6 million in Q2 2021.
  • Average Share-based Compensation over 5 years is $45.8 million, with a median of $43.3 million recorded in 2022.
  • The largest YoY upside for Share-based Compensation was 74.28% in 2024 against a maximum downside of 37.08% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $35.6 million in 2021, then grew by 22.19% to $43.5 million in 2022, then dropped by 12.41% to $38.1 million in 2023, then surged by 74.28% to $66.4 million in 2024, then dropped by 11.75% to $58.6 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Share-based Compensation are $58.6 million (Q4 2025), $53.7 million (Q3 2025), and $52.8 million (Q2 2025).